CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
3.020
+0.080 (2.72%)
At close: Mar 9, 2026, 4:00 PM EDT
3.040
+0.020 (0.66%)
After-hours: Mar 9, 2026, 7:02 PM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.
The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies.
It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Rami Levin |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 800 946 9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H508 |
| ISIN Number | US18978H5081 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rami Levin M.B.A. | President, Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 8-K | Current Report |
| Feb 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Dec 17, 2025 | 8-K | Current Report |
| Nov 21, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 4, 2025 | SCHEDULE 13G | Filing |